



CIRCULOGENE

One Tube
One Week
Complete Results

COMPREHENSIVE LUNG CANCER TESTING

COMPREHENSIVE LUNG PANEL YIELDS DNA, RNA, AND MSI RESULTS IN ONE WEEK.
(TESTING CAN BE DONE ON BOTH BLOOD AND TISSUE)

TUMOR MATCHED WITH TREATMENT



FDA TARGETED THERAPIES AND CLINICAL TRIALS MATCHED TO GENETIC MUTATION

GENE	ALTERATION	MUTANT FRACTION	FDA TARGETED THERAPIES (lung cancer)	FDA TARGETED THERAPIES (for other indications)	CLINICAL TRIALS (DETAILS BELOW)
EGFR	p.E746_A750del Exon 19 deletion	100.0%	Erlotinib Afatinib Gefitinib Nivolumab		155
EGFR DESCRIPTION The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer. [provided by RefSeq, Jun 2016]					

DNA TESTING



GENE:	MUTATION:	FDA-APPROVED TARGETED THERAPIES:
BRAF	V600 MUTATION	DABRAFENIB+TRAMETINIB, VEMURAFENIB
EGFR	EXON 18, G719X MUTATION	AFATINIB
	EXON 19 DELETION/INSERTION	ERLOTINIB, GEFITINIB, AFATINIB, OSIMERTINIB
	EXON 20 INSERTION	NONE (CLINICAL TRIAL)
	EXON 20, T790M MUTATION	OSIMERTINIB
	EXON 21, L858R MUTATION	ERLOTINIB, AFATINIB, GEFITINIB, OSIMERTINIB
	EXON 21, L861Q MUTATION	AFATINIB
KRAS	CODON 12 MUTATION	NONE (AVOID ERLOTINIB, AFATINIB, GEFITINIB)
	CODON 13 MUTATION	NONE (AVOID ERLOTINIB, AFATINIB, GEFITINIB)
	CODON 61 MUTATION	NONE (AVOID ERLOTINIB, AFATINIB, GEFITINIB)

RNA TESTING



ALK GENE FUSION	CRIZOTINIB, CERITINIB, ALECTINIB, BRIGATINIB	
ROSI GENE FUSION	CRIZOTINIB	
PD-L1 GENE EXPRESSION	PEMBROLIZUMAB	
MSI TESTING	MSI-H	PEMBROLIZUMAB